| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 60 | 2025 | 1136 | 13.570 |
Why?
|
| Lung Neoplasms | 86 | 2025 | 2390 | 12.750 |
Why?
|
| Pneumonectomy | 26 | 2025 | 215 | 6.410 |
Why?
|
| Neoplasm Staging | 42 | 2025 | 2025 | 3.520 |
Why?
|
| Thoracic Surgery | 9 | 2025 | 49 | 3.210 |
Why?
|
| Surgeons | 6 | 2022 | 254 | 1.940 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2024 | 1378 | 1.880 |
Why?
|
| Osteopontin | 6 | 2013 | 47 | 1.850 |
Why?
|
| Thoracic Surgical Procedures | 5 | 2024 | 56 | 1.670 |
Why?
|
| Neoadjuvant Therapy | 9 | 2024 | 396 | 1.640 |
Why?
|
| Radiosurgery | 9 | 2021 | 287 | 1.630 |
Why?
|
| Humans | 143 | 2025 | 91302 | 1.500 |
Why?
|
| Physicians, Women | 5 | 2022 | 59 | 1.490 |
Why?
|
| Early Detection of Cancer | 6 | 2025 | 428 | 1.470 |
Why?
|
| Specialties, Surgical | 2 | 2021 | 70 | 1.340 |
Why?
|
| Thoracic Surgery, Video-Assisted | 6 | 2022 | 33 | 1.280 |
Why?
|
| Mesothelioma | 14 | 2023 | 327 | 1.210 |
Why?
|
| Adenocarcinoma | 11 | 2016 | 1185 | 1.200 |
Why?
|
| Pleural Neoplasms | 11 | 2016 | 204 | 1.090 |
Why?
|
| Small Cell Lung Carcinoma | 4 | 2023 | 118 | 1.030 |
Why?
|
| Esophagectomy | 5 | 2009 | 91 | 1.020 |
Why?
|
| Societies, Medical | 7 | 2025 | 599 | 0.940 |
Why?
|
| Disease Management | 3 | 2019 | 337 | 0.830 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2022 | 479 | 0.820 |
Why?
|
| Catheter Ablation | 6 | 2015 | 257 | 0.810 |
Why?
|
| Thymectomy | 1 | 2022 | 31 | 0.810 |
Why?
|
| Jehovah's Witnesses | 1 | 2022 | 21 | 0.800 |
Why?
|
| Mass Screening | 4 | 2025 | 646 | 0.800 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2020 | 2716 | 0.790 |
Why?
|
| Immunotherapy | 6 | 2023 | 705 | 0.770 |
Why?
|
| Myasthenia Gravis | 1 | 2022 | 83 | 0.770 |
Why?
|
| Radium | 4 | 2023 | 7 | 0.770 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 1563 | 0.740 |
Why?
|
| United States | 19 | 2025 | 7214 | 0.710 |
Why?
|
| Symptom Assessment | 1 | 2020 | 67 | 0.690 |
Why?
|
| Antibody Formation | 1 | 2020 | 174 | 0.680 |
Why?
|
| Treatment Outcome | 15 | 2024 | 8466 | 0.680 |
Why?
|
| Esophageal Neoplasms | 4 | 2009 | 333 | 0.680 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 313 | 0.660 |
Why?
|
| Female | 51 | 2025 | 47302 | 0.660 |
Why?
|
| Combined Modality Therapy | 11 | 2022 | 1716 | 0.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 2552 | 0.650 |
Why?
|
| Surgical Flaps | 3 | 2017 | 254 | 0.650 |
Why?
|
| Male | 46 | 2025 | 43394 | 0.630 |
Why?
|
| Aged | 32 | 2024 | 19622 | 0.630 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2016 | 1095 | 0.620 |
Why?
|
| Neoplasms, Second Primary | 5 | 2016 | 241 | 0.600 |
Why?
|
| SEER Program | 4 | 2024 | 202 | 0.600 |
Why?
|
| Middle Aged | 36 | 2024 | 26639 | 0.590 |
Why?
|
| Robotic Surgical Procedures | 2 | 2022 | 337 | 0.590 |
Why?
|
| Retrospective Studies | 16 | 2024 | 9427 | 0.540 |
Why?
|
| Probability | 1 | 2017 | 356 | 0.540 |
Why?
|
| Salvage Therapy | 2 | 2017 | 234 | 0.540 |
Why?
|
| Skin Ulcer | 1 | 2016 | 25 | 0.540 |
Why?
|
| Hyaluronan Receptors | 2 | 2013 | 38 | 0.510 |
Why?
|
| Frozen Sections | 1 | 2015 | 49 | 0.500 |
Why?
|
| Skin Transplantation | 1 | 2016 | 187 | 0.490 |
Why?
|
| Prognosis | 16 | 2021 | 3828 | 0.490 |
Why?
|
| Monitoring, Intraoperative | 1 | 2015 | 109 | 0.480 |
Why?
|
| Esophagus | 2 | 2006 | 107 | 0.480 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2012 | 143 | 0.450 |
Why?
|
| Pancoast Syndrome | 1 | 2013 | 2 | 0.440 |
Why?
|
| Survival Rate | 10 | 2024 | 1901 | 0.440 |
Why?
|
| Radiation Injuries | 3 | 2024 | 159 | 0.440 |
Why?
|
| Radiopharmaceuticals | 3 | 2012 | 198 | 0.440 |
Why?
|
| Fas Ligand Protein | 1 | 2013 | 49 | 0.420 |
Why?
|
| Adult | 28 | 2024 | 27222 | 0.410 |
Why?
|
| Positron-Emission Tomography | 5 | 2013 | 343 | 0.410 |
Why?
|
| Fluorine Radioisotopes | 1 | 2012 | 25 | 0.380 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 99 | 0.380 |
Why?
|
| Aged, 80 and over | 16 | 2023 | 6855 | 0.380 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 605 | 0.370 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 245 | 0.360 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 116 | 0.360 |
Why?
|
| Thoracic Neoplasms | 2 | 2024 | 66 | 0.360 |
Why?
|
| Bronchogenic Cyst | 1 | 2010 | 5 | 0.360 |
Why?
|
| Thoracic Diseases | 1 | 2010 | 27 | 0.350 |
Why?
|
| Soft Tissue Infections | 1 | 2010 | 26 | 0.350 |
Why?
|
| Thoracic Wall | 1 | 2010 | 24 | 0.350 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 1144 | 0.350 |
Why?
|
| Survival Analysis | 4 | 2019 | 1501 | 0.330 |
Why?
|
| Risk Assessment | 7 | 2022 | 2346 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 481 | 0.330 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2022 | 291 | 0.330 |
Why?
|
| Simulation Training | 2 | 2021 | 105 | 0.320 |
Why?
|
| Education, Medical, Graduate | 3 | 2020 | 407 | 0.320 |
Why?
|
| Lung Transplantation | 2 | 2024 | 344 | 0.300 |
Why?
|
| Health Status Disparities | 1 | 2011 | 193 | 0.300 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 541 | 0.300 |
Why?
|
| Perfusion | 3 | 2024 | 255 | 0.300 |
Why?
|
| Consensus | 4 | 2024 | 376 | 0.270 |
Why?
|
| Dumping Syndrome | 1 | 2006 | 5 | 0.260 |
Why?
|
| Gastric Emptying | 1 | 2006 | 25 | 0.260 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2352 | 0.260 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 591 | 0.260 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 433 | 0.250 |
Why?
|
| Stomach | 1 | 2006 | 111 | 0.240 |
Why?
|
| Esophageal Diseases | 1 | 2005 | 27 | 0.240 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 325 | 0.240 |
Why?
|
| Patient Selection | 3 | 2020 | 685 | 0.240 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 310 | 0.240 |
Why?
|
| Transcription Factors | 1 | 2013 | 1672 | 0.240 |
Why?
|
| Patient Care Management | 2 | 2020 | 30 | 0.240 |
Why?
|
| Career Mobility | 1 | 2025 | 37 | 0.230 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2006 | 114 | 0.230 |
Why?
|
| Lung | 5 | 2024 | 1326 | 0.230 |
Why?
|
| Computer Simulation | 3 | 2021 | 1106 | 0.230 |
Why?
|
| Intubation, Intratracheal | 1 | 2006 | 150 | 0.230 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 120 | 0.230 |
Why?
|
| General Surgery | 1 | 2007 | 241 | 0.230 |
Why?
|
| Chemoradiotherapy | 3 | 2024 | 318 | 0.230 |
Why?
|
| Risk Factors | 5 | 2022 | 5622 | 0.220 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2024 | 36 | 0.220 |
Why?
|
| Gastroesophageal Reflux | 1 | 2006 | 126 | 0.220 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 3724 | 0.220 |
Why?
|
| Postoperative Complications | 4 | 2024 | 2352 | 0.220 |
Why?
|
| Smoking | 2 | 2024 | 630 | 0.220 |
Why?
|
| Medicare | 2 | 2024 | 432 | 0.210 |
Why?
|
| Thymoma | 1 | 2023 | 31 | 0.210 |
Why?
|
| Hamartoma | 1 | 2003 | 35 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 855 | 0.210 |
Why?
|
| Lymphatic Metastasis | 4 | 2010 | 500 | 0.210 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 125 | 0.210 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2014 | 10 | 0.210 |
Why?
|
| Thymus Neoplasms | 1 | 2023 | 44 | 0.210 |
Why?
|
| Medical Oncology | 1 | 2007 | 390 | 0.210 |
Why?
|
| Radiotherapy, Conformal | 1 | 2023 | 85 | 0.200 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2002 | 30 | 0.200 |
Why?
|
| Chylothorax | 1 | 2022 | 10 | 0.200 |
Why?
|
| Faculty, Medical | 1 | 2025 | 195 | 0.200 |
Why?
|
| Chylous Ascites | 1 | 2022 | 9 | 0.200 |
Why?
|
| Frailty | 1 | 2024 | 84 | 0.200 |
Why?
|
| Time Factors | 4 | 2023 | 5394 | 0.190 |
Why?
|
| Health Care Costs | 1 | 2023 | 238 | 0.190 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 1070 | 0.190 |
Why?
|
| ErbB Receptors | 2 | 2022 | 500 | 0.190 |
Why?
|
| Steroids | 1 | 2022 | 173 | 0.190 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 47 | 0.190 |
Why?
|
| Funnel Chest | 1 | 2021 | 9 | 0.180 |
Why?
|
| Pneumothorax | 2 | 2020 | 53 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 105 | 0.180 |
Why?
|
| Lung Diseases | 1 | 2003 | 279 | 0.180 |
Why?
|
| Cohort Studies | 6 | 2024 | 2909 | 0.180 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 45 | 0.180 |
Why?
|
| Immunization, Passive | 1 | 2020 | 71 | 0.180 |
Why?
|
| Betacoronavirus | 2 | 2020 | 266 | 0.170 |
Why?
|
| Critical Pathways | 1 | 2020 | 37 | 0.170 |
Why?
|
| Pandemics | 3 | 2021 | 795 | 0.170 |
Why?
|
| Case-Control Studies | 4 | 2013 | 1884 | 0.170 |
Why?
|
| Sexual Harassment | 1 | 2019 | 9 | 0.160 |
Why?
|
| Career Choice | 1 | 2021 | 150 | 0.160 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 283 | 0.160 |
Why?
|
| Protein Isoforms | 2 | 2010 | 281 | 0.160 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2018 | 10 | 0.160 |
Why?
|
| Sexism | 1 | 2019 | 55 | 0.160 |
Why?
|
| Drainage | 1 | 2020 | 169 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 866 | 0.160 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 28 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 477 | 0.150 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 1611 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 168 | 0.150 |
Why?
|
| Thoracotomy | 1 | 2018 | 64 | 0.150 |
Why?
|
| Respiratory System | 1 | 2018 | 119 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 616 | 0.140 |
Why?
|
| Safety-net Providers | 1 | 2018 | 37 | 0.140 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 15 | 0.140 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 23 | 0.140 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 443 | 0.140 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 61 | 0.140 |
Why?
|
| Lymph Nodes | 2 | 2011 | 554 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 4 | 2016 | 82 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1695 | 0.130 |
Why?
|
| Asbestos | 2 | 2012 | 22 | 0.120 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 72 | 0.120 |
Why?
|
| Apoptosis | 2 | 2013 | 1725 | 0.120 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 147 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 308 | 0.120 |
Why?
|
| Biopsy | 2 | 2016 | 1197 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 205 | 0.120 |
Why?
|
| Subcutaneous Emphysema | 1 | 2014 | 8 | 0.120 |
Why?
|
| Photochemotherapy | 1 | 1995 | 100 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1182 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 888 | 0.120 |
Why?
|
| Simian virus 40 | 4 | 1998 | 35 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2012 | 338 | 0.110 |
Why?
|
| Radiography | 2 | 2014 | 810 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2023 | 4375 | 0.110 |
Why?
|
| Receptor, EphB2 | 1 | 2013 | 3 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 572 | 0.110 |
Why?
|
| Peritoneum | 1 | 2013 | 57 | 0.110 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 47 | 0.110 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 185 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2013 | 158 | 0.100 |
Why?
|
| Microbiota | 1 | 2018 | 411 | 0.100 |
Why?
|
| Operative Time | 1 | 2013 | 151 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2699 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2013 | 795 | 0.100 |
Why?
|
| ROC Curve | 2 | 2012 | 786 | 0.100 |
Why?
|
| Epithelium | 1 | 2013 | 324 | 0.100 |
Why?
|
| Organ Preservation | 2 | 2024 | 130 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2007 | 169 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2012 | 128 | 0.100 |
Why?
|
| Pain Management | 1 | 2013 | 146 | 0.100 |
Why?
|
| Cytokines | 3 | 2022 | 824 | 0.100 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2013 | 138 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 126 | 0.100 |
Why?
|
| Biomarkers | 2 | 2016 | 1824 | 0.100 |
Why?
|
| Job Satisfaction | 1 | 2012 | 79 | 0.090 |
Why?
|
| Palliative Care | 1 | 2013 | 264 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2012 | 88 | 0.090 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2011 | 24 | 0.090 |
Why?
|
| Young Adult | 5 | 2021 | 6527 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 39 | 0.090 |
Why?
|
| Sternoclavicular Joint | 1 | 2010 | 2 | 0.090 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2010 | 8 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 41 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1404 | 0.090 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 40 | 0.090 |
Why?
|
| Cell Movement | 2 | 2013 | 793 | 0.090 |
Why?
|
| Ribonucleases | 1 | 2011 | 93 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 694 | 0.090 |
Why?
|
| Computer-Assisted Instruction | 1 | 2011 | 44 | 0.090 |
Why?
|
| Debridement | 1 | 2010 | 61 | 0.090 |
Why?
|
| Models, Anatomic | 1 | 2011 | 92 | 0.090 |
Why?
|
| Functional Laterality | 1 | 2011 | 199 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2009 | 1049 | 0.090 |
Why?
|
| Mutation | 1 | 2022 | 4210 | 0.090 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 107 | 0.090 |
Why?
|
| Joint Diseases | 1 | 2010 | 49 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2011 | 317 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2011 | 2627 | 0.090 |
Why?
|
| Necrosis | 1 | 2010 | 211 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2010 | 100 | 0.080 |
Why?
|
| Tracheal Neoplasms | 1 | 2009 | 8 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2019 | 1073 | 0.080 |
Why?
|
| Pain, Postoperative | 1 | 2012 | 259 | 0.080 |
Why?
|
| Glomus Tumor | 1 | 2009 | 9 | 0.080 |
Why?
|
| Chest Pain | 1 | 2009 | 42 | 0.080 |
Why?
|
| Sarcoidosis | 1 | 2010 | 73 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2010 | 429 | 0.080 |
Why?
|
| Endosonography | 1 | 2010 | 100 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2025 | 1067 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2010 | 123 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2012 | 199 | 0.080 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 261 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 375 | 0.080 |
Why?
|
| Mediastinal Neoplasms | 2 | 2005 | 45 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2013 | 2034 | 0.070 |
Why?
|
| MicroRNAs | 2 | 2011 | 570 | 0.070 |
Why?
|
| Length of Stay | 2 | 2020 | 761 | 0.070 |
Why?
|
| Wound Healing | 1 | 2010 | 365 | 0.070 |
Why?
|
| Microwaves | 1 | 2008 | 36 | 0.070 |
Why?
|
| Radiation Oncologists | 2 | 2018 | 15 | 0.070 |
Why?
|
| Chest Tubes | 2 | 2020 | 24 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 458 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 409 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2011 | 469 | 0.070 |
Why?
|
| DNA, Viral | 2 | 1998 | 265 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 1085 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 2 | 1998 | 45 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 355 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 478 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 1473 | 0.070 |
Why?
|
| Pulmonary Ventilation | 1 | 2006 | 33 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1174 | 0.070 |
Why?
|
| Sialoglycoproteins | 1 | 2006 | 31 | 0.060 |
Why?
|
| Carbonic Anhydrases | 1 | 2006 | 15 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2006 | 170 | 0.060 |
Why?
|
| Cognition | 1 | 2011 | 593 | 0.060 |
Why?
|
| Mediastinoscopy | 1 | 2005 | 5 | 0.060 |
Why?
|
| History, 21st Century | 2 | 2017 | 186 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 2 | 1998 | 183 | 0.060 |
Why?
|
| Thoracic Injuries | 1 | 2006 | 38 | 0.060 |
Why?
|
| California | 1 | 2006 | 152 | 0.060 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 9 | 0.060 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 471 | 0.060 |
Why?
|
| Esophagoplasty | 1 | 2005 | 10 | 0.060 |
Why?
|
| Anesthetics | 1 | 2005 | 53 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2005 | 117 | 0.060 |
Why?
|
| Risk | 1 | 2006 | 658 | 0.060 |
Why?
|
| Eligibility Determination | 1 | 2024 | 36 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 342 | 0.060 |
Why?
|
| Frail Elderly | 1 | 2024 | 85 | 0.050 |
Why?
|
| Incidence | 2 | 2022 | 1601 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 9441 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2024 | 235 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2024 | 132 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 85 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 403 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2024 | 322 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2022 | 22 | 0.050 |
Why?
|
| Work-Life Balance | 1 | 2022 | 6 | 0.050 |
Why?
|
| Asthma | 1 | 2009 | 998 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 316 | 0.050 |
Why?
|
| Transfection | 3 | 2011 | 910 | 0.050 |
Why?
|
| Leukocytes | 1 | 2022 | 210 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 109 | 0.050 |
Why?
|
| Oxygen | 1 | 2006 | 755 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2003 | 435 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2020 | 801 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 146 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 66 | 0.040 |
Why?
|
| Epitopes | 1 | 2021 | 255 | 0.040 |
Why?
|
| Bioethics | 1 | 2020 | 35 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 193 | 0.040 |
Why?
|
| Risk Management | 1 | 2020 | 43 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 204 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 136 | 0.040 |
Why?
|
| Child | 2 | 2022 | 7291 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 494 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 42 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 264 | 0.040 |
Why?
|
| Asbestosis | 2 | 1998 | 5 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 130 | 0.040 |
Why?
|
| Living Donors | 1 | 2022 | 340 | 0.040 |
Why?
|
| Sputum | 1 | 2018 | 35 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 125 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2022 | 519 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2021 | 498 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 128 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1998 | 83 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1998 | 67 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 302 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1998 | 158 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 255 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 581 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 804 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 890 | 0.030 |
Why?
|
| Liver | 1 | 2022 | 1227 | 0.030 |
Why?
|
| RNA, Antisense | 1 | 1996 | 15 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 169 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 2021 | 0.030 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1996 | 18 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 1996 | 793 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 307 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 966 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 200 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 744 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 255 | 0.030 |
Why?
|
| Anniversaries and Special Events | 1 | 2016 | 15 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1705 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2021 | 792 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 1995 | 113 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2017 | 122 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 1998 | 277 | 0.030 |
Why?
|
| Base Sequence | 2 | 1996 | 2330 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1995 | 154 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1995 | 168 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1995 | 128 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1995 | 152 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 316 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2383 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3033 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 668 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 1995 | 384 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2018 | 546 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1807 | 0.030 |
Why?
|
| DNA Damage | 1 | 1995 | 375 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 303 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 324 | 0.030 |
Why?
|
| Cricetinae | 3 | 1998 | 560 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 1995 | 376 | 0.030 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2012 | 16 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1996 | 706 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2012 | 47 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 1995 | 496 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 288 | 0.020 |
Why?
|
| Fear | 1 | 2012 | 80 | 0.020 |
Why?
|
| Self Concept | 1 | 2012 | 135 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 557 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1173 | 0.020 |
Why?
|
| Thoracoscopes | 1 | 2011 | 2 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 329 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 2011 | 11 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 125 | 0.020 |
Why?
|
| Dissection | 1 | 2011 | 44 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2011 | 100 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2010 | 37 | 0.020 |
Why?
|
| Motor Skills | 1 | 2011 | 79 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2011 | 66 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 325 | 0.020 |
Why?
|
| Mediastinum | 1 | 2010 | 48 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 982 | 0.020 |
Why?
|
| Affect | 1 | 2012 | 390 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 233 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 521 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1102 | 0.020 |
Why?
|
| Empyema | 1 | 2008 | 9 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2893 | 0.020 |
Why?
|
| Depression | 1 | 2012 | 518 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2006 | 1302 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1998 | 115 | 0.020 |
Why?
|
| Plasmids | 2 | 1998 | 292 | 0.020 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2006 | 11 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2006 | 20 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 592 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1878 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2005 | 36 | 0.020 |
Why?
|
| Tracheal Diseases | 1 | 2005 | 14 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 925 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1750 | 0.010 |
Why?
|
| Animals | 4 | 1998 | 27852 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2788 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 267 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 1499 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1998 | 93 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 1998 | 115 | 0.010 |
Why?
|
| Virus Replication | 1 | 1998 | 328 | 0.010 |
Why?
|
| Oxygenators | 1 | 1996 | 3 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 1996 | 42 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1996 | 154 | 0.010 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1996 | 42 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1996 | 74 | 0.010 |
Why?
|
| Safety | 1 | 1996 | 144 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1998 | 458 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 692 | 0.010 |
Why?
|
| Sarcoma | 1 | 1996 | 217 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1996 | 449 | 0.010 |
Why?
|
| Remission Induction | 1 | 1996 | 758 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1996 | 326 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1996 | 333 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1996 | 908 | 0.010 |
Why?
|
| Melanoma | 1 | 1996 | 477 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1164 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 4060 | 0.010 |
Why?
|